Mogamulizumab

Medical uses

Mogamulizumab is indicated for the treatment of adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.

History

The precursor to mogamulizumab was a mouse anti-human CCR4 IgG1 mAb (KM2160), that was made in 1996 in a collaboration between Kouji Matsushima of University of Tokyo and Kyowa Hakko Kirin. Kyowa humanized it, and expressed the humanized gene in a CHO cell line in which FUT8 had been knocked out, which produced antibodies with no fucose in the Fc region. This is thought to enhance its antibody-dependent cell-mediated cytotoxicity. It was first tested in humans in 2007.

Kyowa licensed rights for use outside of cancer to Amgen in 2008, for $100 million up front and $420 million in biodollars. Amgen terminated the agreement in 2014.

In 2017, the US FDA granted the application for mogamulizumab a priority review for cutaneous T cell lymphoma. Full approval was granted by the FDA in August 2018. The FDA approval was based on a clinical trial of 372 participants with relapsed mycosis fungoides or Sézary syndrome who received either mogamulizumab or a type of chemotherapy called vorinostat. The FDA granted the application for mogamulizumab priority review, breakthrough therapy, and orphan drug designations. The FDA granted the approval of Poteligeo to Kyowa Kirin, Inc.

Society and culture

Legal status

The US Food and Drug Administration (FDA) approved mogamulizumab in August 2018, for the treatment of relapsed or refractory mycosis fungoides and Sézary disease. Mogamulizumab was approved in Japan in 2012, for the treatment of relapsed or refractory CCR4+ adult T-cell leukemia/lymphoma and in 2014, for relapsed or refractory CCR4+ cutaneous T cell lymphoma.

Mogamulizumab was approved for medical use in the European Union in November 2018, and in Canada in June 2022.

Research

Mogamulizumab is being explored as a treatment for HTLV-1–Associated Myelopathy. An early Phase 1-2a study showed decreased in proviral loads, as well as inflammatory markers in the CSF. 79% of the patients showed reduction in spasticity and 32% showed decrease in motor disability.

References

References

1. (15 February 2021). "Poteligeo".
2. (10 May 2021). "AusPAR: Mogamulizumab".
3. (25 April 2012). "Poteligeo Product information".
4. (23 October 2014). "Summary Basis of Decision - Poteligeo".
5. (27 April 2023). "Poteligeo- mogamulizumab-kpkc injection".
6. (14 October 2016). "Poteligeo EPAR".
7. (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering". BioDrugs.
8. (January 2019). "New Drug Therapy Approvals 2018".
9. (2015). "Clinical Application of Anti-CCR4 Monoclonal Antibody". Oncology.
10. "Available Agents: Mogamulizumab". NCI Formulary.
11. (May 2014). "Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4". Expert Opinion on Drug Discovery.
12. (25 August 2017). "After a long clinical odyssey, the FDA tapped this PhIII anti-CCR4 as a 'breakthrough' lymphoma drug". Endpoints.
13. (22 January 2018). "Mogamulizumab Receives Priority Review for CTCL - ASH Clinical News". ASH Clinical News.
14. (7 September 2018). "Drug Approval Package: Poteligeo (mogamulizumab-kpkc)".
15. (8 August 2018). "FDA approves treatment for two rare types of non-Hodgkin lymphoma".
16. (February 2018). "Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy". The New England Journal of Medicine.